MedTrace Logo

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

NCT06576271 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2026-04-29

No results posted yet for this study

Summary

This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), healthy participants of Chinese and Japanese descent (Part C), and participants with interstitial lung disease associated with connective tissue disease (Part D)

Conditions

Interventions

DRUG

GSK4527363

GSK4527363 will be administered to participants.

DRUG

Placebo matching GSK4527363

Placebo matching GSK4527363 will be administered to participants.

DRUG

Belimumab

Belimumab will be administered to participants.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-02
Primary Completion
2028-01-11
Completion
2028-01-11
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06576271 on ClinicalTrials.gov